Eli Lilly has done it! Sort of…at least in trials.
LDL cholesterol is the single most important modifiable driver of heart attacks in men, and the causal link is among the best-established findings in modern medicine. LDL particles deposit cholesterol in arterial walls, seeding the atherosclerotic plaques that eventually rupture and trigger myocardial infarction, and the relationship is dose-dependent and cumulative, meaning lifetime LDL exposure matters more than any single measurement.
Men are especially vulnerable because they lack the protective effect of estrogen on lipid metabolism and endothelial function that shields premenopausal women, which is why men develop clinically significant coronary disease roughly 7-10 years earlier than women on average and why heart disease remains the leading cause of death for men in virtually every developed country.
Genetic experiments of nature reinforce the causal story. Men born with naturally low LDL (for example, carriers of PCSK9 loss-of-function variants) have markedly lower rates of heart attack across their lifetimes, while men with familial hypercholesterolemia frequently suffer infarctions in their 30s and 40s. Every major class of LDL-lowering therapy tested in randomized trials (statins, ezetimibe, and PCSK9 inhibitors) has produced corresponding reductions in cardiovascular events, with the magnitude of benefit tracking closely to the magnitude and duration of LDL reduction.
Lowering LDL earlier and keeping it lower for longer produces the biggest reduction in heart attack risk, which is precisely why a one-time gene-editing therapy that durably suppresses PCSK9 is such a consequential development.
Why do these results matter:
A single IV infusion of VERVE-102 cut PCSK9 by up to 88% and LDL-C by up to 62%, sustained across the follow-up window. This is the first credible human demonstration that in vivo base editing can durably rewrite a metabolic phenotype, implying chronic daily statins and biweekly PCSK9 injections may eventually be replaced by a one-time procedure for high-risk patients.
The "permanent" claim is real at the DNA level, but durability data is still thin. The A→G edit is heritable in edited hepatocytes, but only 15 of 35 participants have crossed one year and the higher-dose cohorts haven't yet. Implication: pricing, regulatory framing, and patient counseling will hinge on multi-year persistence data that doesn't exist yet, so expect a long Phase 2/3 runway before "one and done" can be marketed as such.
Biomarker win, not yet an outcomes win. The trial measured LDL-C, not heart attacks or strokes. Mendelian-randomization evidence makes the inference strong, but a cardiovascular outcomes trial (likely 3-5 years, tens of thousands of patients) is the gate to broad adoption and payer coverage.
Safety looks clean, but the bar is unusually high for a permanent edit. No dose-limiting toxicities, only mild infusion reactions and transient ALT bumps. Critically, this is the redesigned LNP after VERVE-101 was paused in 2023 for thrombocytopenia and a cardiac event. Regulators will likely demand far more follow-up than for a reversible drug, because there's no "stop taking it" option if a long-tail risk emerges.
The platform implication is bigger than the drug. If GalNAc-LNP delivery of an mRNA-encoded base editor works safely for PCSK9, the same delivery system plausibly extends to ANGPTL3, LPA, APOC3, and other liver-expressed targets driving cardiometabolic disease. The headline today is LDL, but the real story for Lilly's opt-in calculus, and for the field, is whether the liver just became a programmable organ.
Read the original study here.
I do believe that we are just 10 years away from solving most (all) diseases: dementia, cancer, & co.
Verdict: Buy
WIMM for companies: If you would like to offer the newsletter as a benefit to other employees in your company, please contact me directly. ([email protected])
Work with me: If you are interested in working with me on your personal portfolio, again, contact me. I’m a certified financial consultant.
Finally, “Where is my moat?” is designed for individual readers, though the occasional forward is absolutely fine.
Thanks for your support & have a wonderful day!
